Total serious adverse events Duration: 1.75 to 3 years · patients with hypertension
First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).
1 finding from 1 review
Total mortality
Beta‐blockers showed no clear difference in total mortality compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Total cardiovascular disease
Beta‐blockers probably leads to higher total cardiovascular disease compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Stroke
Beta‐blockers probably leads to higher total stroke compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Total coronary heart disease
Beta‐blockers showed no clear difference in total coronary heart disease compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events
Beta‐blockers showed no clear difference in withdrawal due to adverse effect compared with calcium‐channel blockers (low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs may leads to lower cardiovascular mortality compared with β‐blocker (low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ACE inhibitor (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with ACE inhibitor (low certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs may leads to lower stroke compared with ACE inhibitor (low certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs may leads to higher congestive heart failure compared with ACE inhibitor (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ACE inhibitor (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ARB (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs probably leads to lower myocardial infarction compared with ARB (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs showed no clear difference in stroke compared with ARB (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs may leads to higher congestive heart failure compared with ARB (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ARB (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs showed no clear difference in stroke compared with diuretic (moderate certainty).
1 finding from 1 review